Taula de Continguts
Understanding Tirzepatide (Mounjaro) and Semaglutide (Ozempic)
Tirzepatide and semaglutide are injectable drugs that have become important tools in the management of type 2 diabetes and, more recently, in weight management. Although they share similar goals, their mechanisms of action present fundamental differences. Understanding these distinctions is key to understanding how they act in the body.
Both medications belong to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. However, tirzepatide adds a second action, making it a unique option. At Santé Clínica Estética, our medical approach focuses on offering supervised options for weight management, always under the guidance of our professionals.
Semaglutide (Ozempic, Wegovy, Rybelsus): GLP-1 Agonist
Semaglutide is a GLP-1 receptor agonist. This means it mimics the action of a natural hormone called GLP-1, which the intestine releases after eating. This hormone has several beneficial effects on the body.
Primarily, GLP-1 stimulates insulin secretion in a glucose-dependent manner, which helps reduce blood sugar levels. It also slows gastric emptying, contributing to a greater feeling of fullness and potentially decreasing food intake. Additionally, it acts in the brain to reduce appetite.
According to a study published in The New England Journal of Medicine, semaglutide at doses of 2.4 mg weekly (Wegovy) demonstrated an average weight loss of 14.9% of initial body weight in adults with overweight or obesity in a 68-week trial.
Tirzepatide (Mounjaro, Zepbound): Dual GLP-1 and GIP Agonist
Tirzepatide is an innovative medication that acts as a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual action is what differentiates it from semaglutide. GIP is another intestinal hormone that also participates in blood sugar regulation and metabolism.
By activating both receptors (GLP-1 and GIP), tirzepatide enhances the individual effects of each hormone. This translates into more robust blood glucose control and a more significant reduction in appetite and caloric intake. The synergy between GLP-1 and GIP can lead to more pronounced results in weight loss and glycemic control.
A phase 3 clinical trial (SURMOUNT-1), published in The New England Journal of Medicine, showed that tirzepatide at doses of 15 mg weekly resulted in an average weight loss of 20.9% in adults with obesity or overweight without diabetes, over a period of 72 weeks.
Key Comparison: Mechanism and Effects
The main difference lies in the number of hormonal pathways they activate. Semaglutide focuses on one (GLP-1), while tirzepatide addresses two (GLP-1 and GIP). This table summarizes the main distinctions:
| Characteristic | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|
| Agonist Type | GLP-1 | GLP-1 and GIP (dual) |
| Primary Action | Stimulates insulin, slows gastric emptying, reduces appetite | Identical to semaglutide, plus additional GIP effects |
| Additional GIP Effects | Not applicable | May enhance insulin secretion, improve insulin sensitivity, and reduce fat accumulation |
| Weight Loss Potential | Effective (e.g., 15% of body weight) | Potentially greater (e.g., 21% of body weight) |
| Approved Use | Type 2 diabetes, weight management (higher doses) | Type 2 diabetes, weight management (higher doses) |
Both medications are administered via subcutaneous injections, usually once a week. The dose is gradually adjusted under medical supervision to minimize potential gastrointestinal side effects. Individual results may vary significantly.
Key Takeaways
- Semaglutide (Ozempic) is a GLP-1 agonist, mimicking a hormone to reduce glucose and appetite.
- Tirzepatide (Mounjaro) is a dual GLP-1 and GIP agonist, mimicking two hormones for a more comprehensive effect.
- Tirzepatide's dual action may result in greater weight loss and better glycemic control in some patients.
- Both drugs are weekly injectables and require medical supervision for dosing and monitoring.
- The choice between the two depends on individual medical evaluation and patient goals.
How Santé Clínica Estética Approaches It
At Santé Clínica Estética, we understand that weight management is a personal and complex journey that requires a medical and personalized approach. Our team of board-certified doctors offers a GLP-1 weight management program that includes a comprehensive assessment. This initial assessment is crucial to determine if a semaglutide or tirzepatide treatment is suitable for you.
The personalized protocol involves regular follow-up, dose adjustments, and education on healthy lifestyle habits. We strongly believe in continuous support to optimize results and ensure your well-being. The medical assessment consultation for weight management costs €50 and can be conducted in Spanish, English, Portuguese, or Russian.
Our goal is to help you achieve your health and wellness goals safely and effectively, always under the strict supervision of medical professionals. It is important to remember that these medications are a tool within a comprehensive plan that includes diet and exercise, and results may vary.
Frequently Asked Questions
Are these medications a substitute for bariatric surgery?
No, neither semaglutide nor tirzepatide are a substitute for bariatric surgery. They are medical tools for weight management and glycemic control, especially in cases of overweight or obesity, but they do not replace surgical procedures. The decision to opt for one or the other should be evaluated by a specialist doctor.
What are the common side effects?
The most common side effects of both medications are gastrointestinal, including nausea, vomiting, diarrhea, or constipation. These are usually mild and transient, especially at the beginning of treatment. They are mitigated by gradual dose titration under medical supervision.
Do I need a prescription to get Mounjaro or Ozempic?
Yes, both Mounjaro (tirzepatide) and Ozempic (semaglutide) are prescription-only medications. Their use must always be under the supervision and control of a doctor. At Santé Clínica Estética, the first consultation is a complete medical assessment to determine the suitability of the treatment and issue the corresponding prescription.
How long does it take to see weight loss results?
Weight loss results with semaglutide or tirzepatide are not immediate and vary among individuals. Generally, significant weight loss begins to be noticeable after several weeks or months of continuous treatment, as the dose is increased. Clinical studies demonstrating significant weight loss were conducted over periods of 68 to 72 weeks.
